title: Hesa-A Improves Clinical Outcome of Oral Carcinoma by Affecting p53 Gene Expression in vivo.
abstract: BACKGROUND
  Oral carcinoma (OC) remains as one of the most difficult malignancies to cure. Hesa-A is an Iranian herbal-marine compound that has shown promising anti-tumor properties on various human cancer cells, although the mechanisms of action remain to be addressed. This study was conducted to evaluate the effect of two doses of Hesa-A on mRNA expression of p53 as a main prognosticator of OC.
  
  
  METHODS
  60 rats were randomly divided into 5 groups of 12 animals each. Rats in carcinoma groups received 0, 250 and 500 mg/kg body weight of Hesa-A three times a day. The two other groups considered as treated and untreated healthy groups. At the end of experiment, animals were sacrificed and tongue tissues subjected to H and E staining and real time PCR.
  
  
  RESULTS
  Our results indicated that compared to healthy group, p53 over expressed ~ 40% in untreated carcinoma group. After treatment with 250 mg/kg and 500 mg/kg body weights of Hesa-A , p53 level dropped by 53.4% and 13.6 %, respectively, compared to untreated carcinoma group (p<0.05, p<0.0001). Moreover, there was a significant relation between p53 mRNA content and observed pathological changes in studied groups (p<0.05).
  
  
  CONCLUSIONS
  These data provide insights into the mechanism(s) by which Hesa-A improves clinical outcome of oral carcinoma by modulation of p53 expression.
authors.affiliation: Drug Applied Research Center, Tabriz, Iran E-mail : jahanbanr@tbzmed.ac.ir.
authors.forename: Mehran Mesgari
authors.initials: MM
authors.lastname: Abbasi
authors.forename: Sanaz
authors.initials: S
authors.lastname: Helli
authors.forename: Amir
authors.initials: A
authors.lastname: Monfaredan
authors.forename: Rana
authors.initials: R
authors.lastname: Jahanban-Esfahlan
mesh_terms: D015112:4-Nitroquinoline-1-oxide; D000818:Animals; D002277:Carcinoma / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D015870:Gene Expression / Q000187:drug effects*; D016158:Genes, p53 / Q000187:drug effects*; D008297:Male; D008517:Phytotherapy; D028321:Plant Preparations / Q000494:pharmacology* / Q000627:therapeutic use; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D014062:Tongue Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
chemical_list: C502848:HESA-A preparation; D028321:Plant Preparations; D012333:RNA, Messenger; D015112:4-Nitroquinoline-1-oxide